Type 2 diabetes mellitus augments Parkinson’s disease risk or the other way around: Facts, challenges and future possibilities

Faizan, Mohd; Sarkar, Alika; Singh, Mahendra Pratap

doi:10.1016/j.arr.2022.101727

Cited by 9 publications

(2 citation statements)

References 122 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Simultaneously, researchers have mostly targeted their studies to the general population, with few studies focusing on diabetic patients. 23 Nevertheless, the prevalence of T2DM in the population is increasing year by year, 24 and the prevalence of diabetic osteoporosis is also increasing gradually. 25 Meanwhile, the early stages of bone density loss in diabetic patients are asymptomatic.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Opportunistic Screening with Chest CT in Identifying Osteoporosis and Osteopenia in Patients with T2DM

Xue,

Lu,

Sun

et al. 2024

DMSO

View full text Add to dashboard Cite

To explore the validity of the thoracic spine Hounsfield Unit (HU) measured by chest computed tomography (CT) for opportunistic screening of diabetic osteoporosis. The current study attempted to establish a diagnostic threshold for thoracic spine HU in a type 2 diabetes mellitus (T2DM) population with osteoporosis. Patients and Methods: The current study retrospectively included 334 patients with T2DM. They underwent chest CT and Dualenergy X-ray (DXA) between August 2021 and January 2022 in our hospital. HU values were measured on the resulting chest CT images at thoracic spine 11 and 12 to construct regions of interest. All patients were grouped according to the lowest T-value of DXA examination: osteoporosis, osteopenia and normal bone density. HU values were compared with T-values in each group of patients, and receiver operating characteristics curves were plotted to calculate diagnostic thresholds as well as sensitivity and specificity. Results: There was a strong correlation between the HU values of chest CT and the T-values of DXA (p < 0.01). The sensitivity for osteoporosis was 88.7% for T11 attenuation≤ 98 HU and the specificity for osteoporosis was 87.5% for T12 attenuation ≤ 117HU; the specificity for normal BMD was 85.4% for T11 attenuation ≥ 147 HU and 82% for T12 attenuation ≥ 146 HU. Conclusion:Chest CT can be used to screen patients with T2DM for opportunistic osteoporosis and help determine if they need DXA screening. The current study suggests that when the HU threshold of T11 ≤ 98/T12 ≤ 117, patients may need further osteoporosis screening.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of Opportunistic Screening with Chest CT in Identifying Osteoporosis and Osteopenia in Patients with T2DM

Xue,

Lu,

Sun

et al. 2024

DMSO

View full text Add to dashboard Cite

show abstract

“…In recent decades, the prevalence of type 2 diabetes mellitus (T2DM) has increased rapidly. According to the prediction of the International Diabetes Federation (IDF), there will be over 700 million T2DM cases by 2045, making the disease a significant “killer” that threatens human health in the 21st century ( 1 , 2 ). The global prevalence of diabetes was estimated to be 10.5% in adults aged 20-79 in 2021 (536.6 million cases).…”

Section: Introductionmentioning

confidence: 99%

Selective sodium-glucose cotransporter-2 inhibitors in the improvement of hemoglobin and hematocrit in patients with type 2 diabetes mellitus: a network meta-analysis

Luo,

Bai,

Zhang

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

ObjectiveTo compare the effects of different selective sodium-glucose cotransporter-2 inhibitors (SGLT2i) on hemoglobin and hematocrit in patients with type 2 diabetes mellitus (T2DM) with a network meta-analysis (NMA).MethodsRandomized controlled trials (RCTs) on SGLT2i for patients with T2DM were searched in PubMed, Embase, Cochrane Library, and Web of Science from inception of these databases to July 1, 2023. The risk of bias (RoB) tool was used to evaluate the quality of the included studies, and R software was adopted for data analysis.ResultsTwenty-two articles were included, involving a total of 14,001 T2DM patients. SGLT2i included empagliflozin, dapagliflozin, and canagliflozin. The NMA results showed that compared with placebo, canagliflozin 100mg, canagliflozin 300mg, dapagliflozin 10mg, dapagliflozin 2mg, dapagliflozin 50mg, dapagliflozin 5mg, empagliflozin 25mg, and dapagliflozin 20mg increased hematocrit in patients with T2DM, while canagliflozin 100mg, canagliflozin 200mg, canagliflozin 300mg increased hemoglobin in patients with T2DM. In addition, the NMA results indicated that canagliflozin 100mg had the best effect on the improvement of hematocrit, and canagliflozin 200mg had the best effect on the improvement of hemoglobin.ConclusionBased on the existing studies, we concluded that SGLT2i could increase hematocrit and hemoglobin levels in patients with T2DM, and canagliflozin 100mg had the best effect on the improvement of hematocrit, while canagliflozin 200mg had the best effect on the improvement of hemoglobin.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/#loginpage, identifier PROSPERO (CRD42023477103).

show abstract

Metformin role in Parkinson’s disease: a double-sword effect

et al. 2023

View full text Add to dashboard Cite

Type 2 diabetes mellitus augments Parkinson’s disease risk or the other way around: Facts, challenges and future possibilities

Cited by 9 publications

References 122 publications

Efficacy of Opportunistic Screening with Chest CT in Identifying Osteoporosis and Osteopenia in Patients with T2DM

Efficacy of Opportunistic Screening with Chest CT in Identifying Osteoporosis and Osteopenia in Patients with T2DM

Selective sodium-glucose cotransporter-2 inhibitors in the improvement of hemoglobin and hematocrit in patients with type 2 diabetes mellitus: a network meta-analysis

Metformin role in Parkinson’s disease: a double-sword effect

Contact Info

Product

Resources

About